Evidence map›Paper›PMID 29911169›Full record

ArticleAdvanced biosystems2017

Targeting Tumor-Associated Exosomes with Integrin-Binding Peptides.

Randy P Carney, Sidhartha Hazari, Tatu Rojalin, Alisha Knudson, Tingjuan Gao, Yuchen Tang, Ruiwu Liu, Tapani Viitala, Marjo Yliperttula, Kit S Lam

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced biosystems, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Application of exosomes in tumor immunity: recent progresses.Frontiers in cell and developmental biology · 2024
    Review
  6. Review
  7. Review
  8. Exosomal targeting and its potential clinical application.Drug delivery and translational research · 2022
    Review
  9. Article
  10. Review
  11. Article
  12. Targeting Integrins for Cancer Therapy - Disappointments and Opportunities.Frontiers in cell and developmental biology · 2022
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Designer Exosomes: A New Platform for Biotechnology Therapeutics.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Randy P CarneyDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
Sidhartha HazariDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
Tatu RojalinDivision of Pharmaceutical Biosciences, Centre for Drug Research, University of Helsinki, Helsinki, Finland. Center for Biophotonics, University of California Davis, Sacramento, CA, 95817 USA.
Alisha KnudsonDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
Tingjuan GaoCollege of Chemistry, Central China Normal University, Wuhan 430079, China. Center for Biophotonics, University of California Davis, Sacramento, CA, 95817 USA.
Yuchen TangCollege of Chemistry, Central China Normal University, Wuhan 430079, China. Center for Biophotonics, University of California Davis, Sacramento, CA, 95817 USA.
Ruiwu LiuDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
Tapani ViitalaDivision of Pharmaceutical Biosciences, Centre for Drug Research, University of Helsinki, Helsinki, Finland.
Marjo YliperttulaDivision of Pharmaceutical Biosciences, Centre for Drug Research, University of Helsinki, Helsinki, Finland. Department of Pharmaceutical Sciences, University of Padova, Italy.
Kit S LamDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, USA. University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817, USA.
University of California, Davis · USUniversity of Helsinki · FICentral China Normal University · CNUC Davis Comprehensive Cancer Center

Funding

TRAINING IN COMPARATIVE LUNG BIOLOGY AND MEDICINET32HL007013 · NHLBI · UNIVERSITY OF CALIFORNIA DAVIS · PI Elena Goncharova, Nicholas J. KENYON · 1985 to 2026
$10.1M
Therapeutic Targeting Agents for Ovarian CancerR01CA115483 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI LAM, KIT S · 2005 to 2019
$5.5M
NCI NIH HHS R01 CA115483NHLBI NIH HHS T32 HL007013
6 · The paper itself

Abstract

All cells expel a variety of nano-sized extracellular vesicles (EVs), including exosomes, with composition reflecting the cells' biological state. Cancer pathology is dramatically mediated by EV trafficking via key proteins, lipids, metabolites, and microRNAs. Recent proteomics evidence suggests that tumor-associated exosomes exhibit distinct expression of certain membrane proteins, rendering those proteins as attractive targets for diagnostic or therapeutic application. Yet, it is not currently feasible to distinguish circulating EVs in complex biofluids according to their tissue of origin or state of disease. Here we demonstrate peptide binding to tumor-associated EVs via overexpressed membrane protein. We find that SKOV-3 ovarian tumor cells and their released EVs express α

Indexed as

biosensorcancerdiagnosticsexosomesoptical tweezers

Identifiers

PMID29911169
PMCPMC6001286
OpenAlexW2604113855

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.